4,784
Views
0
CrossRef citations to date
0
Altmetric
Commentary

Gene Therapies to Reduce Chronic Pain: Are we There Yet?

ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon
Pages 209-212 | Received 17 Apr 2020, Accepted 28 Apr 2020, Published online: 17 Jun 2020

References

  • Goldeberg DS , McGeeSJ. Pain as a global public health priority. BMC Public Health11, 770 (2011).
  • Dahlhamer J , LucasJ , ZelayaCet.al Prevalence of chronic pain and high-impact chronic pain among adults. MMWR Morb. Mortal. Wkly Rep.67(36), 1001–1006 (2018).
  • Gaskin DJ , RichardP. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education and Research Appendix C, The Economic Costs of Pain in the United States. IOM Committee on Advancing Pain Research, Care and Education, DC, USA (2011).
  • Escher CM , ParackaL , DresslerD , KolleweK. Botulinum toxin in the management of chronic migraine: clinical evidence and experience. Ther. Adv. Neurol. Disord.10(2), 127–135 (2017).
  • Ballantyne JC . The brain on opioids. Pain159(Suppl. 1), S24–S30 (2018).
  • Vowles KE , McEnteeML , JulnesPSet.al Rates of opioid misuse, abuse and addiction in chronic pain a syttematic review and data synthesis. Pain156(4), 569–576 (2015).
  • Hedegaard H , WarnerM , MininoAM. Drug overdose deaths in the United States, 1999–2016. NCHS Data Brief294, 1–8 (2017). www.cdc.gov/nchs/products/databriefs/db294.htm
  • Young EE , LariviereWR , BelferI. Genetic basis of pain variability: recent advances. J. Med. Genet.49(1), 1–9 (2012).
  • Sexton JE , CoxJJ , ZhaoJ , WoodJN. The genetics of pain: implications for therapeutics. Annu. Rev. Pharmacol. Toxicol.58, 123–142 (2018).
  • Bennett DL , ClarkAJ , HuangJ , WaxmanSG , Dib-HajjSD. The role of voltage-gated sodium channels in pain signaling. Physiological Reviews99(2), 1079–1151 (2019).
  • Cox JJ , ReimannF , NicholasAKet.al An SCN9A channelopathy causes congenital inability to experience pain. Nature444(7121), 894–898 (2006).
  • Waxman SG . Painful Na-channelopathies: an expanding universe. Trends Mol. Med.19(7), 406–409 (2013).
  • Bennett DLH , WoodsCG. Painful and painless channelopathies. Lancet Neurol.13(6), 587–599 (2014).
  • Zimmermann K , LefflerA , BabesAet.al Sensory neuron sodium channel Nav1.8 is essential for pain at low temperatures. Nature447(7146), 855–858 (2007).
  • Faber CG , LauriaG , MerkiesISJet.al Gain-of-function Nav1.8 mutations in painful neuropathy. Proc. Natl Acad. Sci. USA109, 19444–19449 (2012).
  • Huang J , VanoyeCG , CuttsAet.al Sodium channel Nav1.9 mutations associated with insensitivity to pain dampen neuronal excitability. J. Clin. Invest.127(7), 2805–2814 (2017).
  • Habib AM , OkorokovAL , HillMNet.al Microdeletion in a FAAH pseudogene identified in a patient with high anandamide concentrations and pain insensitivity. Br. J. Anaesth.123(2), e249–e253 (2019).
  • Rohl T , KurreckJ. RNA interference in pain research. J. Neurochem.99(2), 371–380 (2006).
  • Pan J , LinXJ , LingZH , CaiYZ. Effect of down-regulation of voltage-gated sodium channel Nav1.7 on activation of astrocytes and microglia in DRG in rats with cancer pain. Asian Pac. J. Trop. Med.8(5), 405–411 (2015).
  • Cai W , CaoJ , RenXet.al shRNA mediated knockdown of Nav1.7 in rat dorsal root ganglion attenuates pain following burn injury. BMC Anesthesiol.16(1), 59 (2016).
  • Second RNAi drug approved. Nat. Biotechnol.38, 385 (2020).
  • Rinaldi C , WoodMJA. Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat. Rev. Neurol.14(1), 9–21 (2018).
  • Mohan A , FitzsimmonsB , ZhaoHTet.al Antisense oligonucleotides selectively suppress target RNA in nociceptive neurons of the pain system and can ameliorate mechanical pain. Pain159(1), 139–149 (2018).
  • Wen XJ , LiZJ , ChenZXet.al Intrathecal administration of Cav3.2 and Cav3.3 antisense oligonucleotide reverses tactile allodynia and thermal hyperalgesia in rats following chronic compression of dorsal root of ganglion. Acta Pharmacol. Sin.27(12), 1547–1552 (2006).
  • Moreno AM , GlaucileneFC , AlemánFet.al Long-lasting analgesia via targeted in vivo epigenetic repression of Nav1.7. bioRxiv711812 (2019). https://www.biorxiv.org/content/10.1101/711812v1
  • Smith I , GreensidePG , NatoliTet.al Evaluation of RNAi and CRISPR technologies by large-scale gene expression profiling in the connectivity map. PLoS Biol.15(11), e2003213 (2017).
  • Stojic L , LunATL , MangeiJet.al Specificity of RNAi, LNA and CRISPRi as loss-of-function methods in transcriptional analysis. Nucleic Acids Res.46(12), 5950–5966 (2018).
  • Laity JH , LeeBM , WrightPE. Zinc finger proteins: new insights into structural and functional diversity. Curr. Opin. Struct. Biol.11(1), 39–46 (2001).
  • Li C , SamulskiRJ. Engineering adeno-associated virus vectors for gene therapy. Nat. Rev. Genet.21, 255–272 (2020).
  • Keeler AM , FlotteTR. Recombinant adeno-associated virus gene therapy in light of Luxturna (and Zolgensma and Glybera): where are we, and how did we get here?Annu. Rev. Virol.6(1), 601–621 (2019).
  • Stevens D , ClabornMK , GildonBL , KesslerTL , WalkerC. Onasemnogene Abeparvovec-xioi: gene therapy for spinal muscular atrophy. Annals of Pharmacotherapyhttps://doi.org/10.11772/F1060028020914274 (2020) ( Epub ahead of print).